ARNA INSERM U1212, CNRS UMR 5320, University of Bordeaux, Bordeaux F-33076, France.
ARNA INSERM U1212, CNRS UMR 5320, University of Bordeaux, Bordeaux F-33076, France.
J Pharm Biomed Anal. 2022 Oct 25;220:115011. doi: 10.1016/j.jpba.2022.115011. Epub 2022 Aug 19.
Lipid nanoparticles (LNPs) have shown great success as drug delivery systems, especially for mRNA vaccines, as those developed during the Covid-19 pandemics. Lipid analysis is critical to monitor the formulation process and control the quality of LNPs. The present study is focused on the development and validation of a high-performance liquid chromatography - diode array detector -evaporative light scattering detector (HPLC-DAD/ELSD) based method for the simultaneous quantification of 7 lipids, illustrating the main components of LNPs: ionizable lipids, the neutral co-lipid cholesterol, phospholipids, hydrophilic polymer-lipids for colloidal stability (e.g., a PEGylated lipid). In particular, this study focuses on two innovative synthetic lipids: a switchable cationic lipid (CSL3) which has demonstrated in vitro and in vivo siRNA transfection abilities, and the palmitic acid-grafted-poly(ethyloxazoline) (PolyEtOx), used as an alternative polymer to address allergic reactions attributed to PEGylated lipids. The HPLC separation was achieved on a Poroshell C18 column at 50 °C using a step gradient of a mobile phase composed of water/methanol mixtures with 0.1% (v/v) trifluoroacetic acid (TFA). This method was validated following ICH Q2(R1) & (R2) guidelines in terms of linearity (R² ≥ 0.997), precision (relative standard deviation on peak areas < 5% for intermediate repeatability), accuracy (recoveries between 92.9% and 108.5%), and sensitivity. Indeed, low detection and quantitation limits were determined (between 0.02 and 0.04 µg and between 0.04 and 0.10 µg, respectively). Due to its high selectivity, this method allowed the analysis of lipid degradation products produced through degradation studies in basic, acidic, and oxidative conditions. Moreover, the method was successfully applied to the analysis of several liposome formulations at two key steps of the development process. Consequently, the reported HPLC method offers fast, versatile, selective and quantitative analysis of lipids, essential for development optimization, chemical characterization, and stability testing of LNP formulations.
脂质纳米粒(LNPs)已作为药物递送系统取得了巨大成功,尤其是在 COVID-19 大流行期间开发的 mRNA 疫苗。脂质分析对于监测制剂过程和控制 LNPs 的质量至关重要。本研究专注于开发和验证一种基于高效液相色谱-二极管阵列检测器-蒸发光散射检测器(HPLC-DAD/ELSD)的方法,用于同时定量 7 种脂质,这些脂质说明了 LNPs 的主要成分:可离子化脂质、中性共脂质胆固醇、磷脂、亲水聚合物脂质用于胶体稳定性(例如,PEG 化脂质)。特别是,本研究专注于两种创新合成脂质:一种具有体外和体内 siRNA 转染能力的可切换阳离子脂质(CSL3),以及作为替代聚合物用于解决与 PEG 化脂质相关的过敏反应的棕榈酸接枝聚(乙氧基唑啉)(PolyEtOx)。HPLC 分离在 50°C 的 Poroshell C18 柱上进行,使用由水/甲醇混合物组成的流动相进行分步梯度洗脱,其中含有 0.1%(v/v)三氟乙酸(TFA)。该方法根据 ICH Q2(R1) & (R2) 指南进行了验证,包括线性度(R²≥0.997)、精密度(峰面积的相对标准偏差 < 5%,中间重复性)、准确度(回收率在 92.9%和 108.5%之间)和灵敏度。实际上,确定了低检测限和定量限(分别为 0.02 和 0.04μg 和 0.04 和 0.10μg)。由于其高选择性,该方法允许分析在碱性、酸性和氧化条件下通过降解研究产生的脂质降解产物。此外,该方法成功应用于两种关键开发步骤的几个脂质体配方的分析。因此,所报道的 HPLC 方法提供了快速、多功能、选择性和定量分析脂质的方法,对于优化 LNP 制剂的开发、化学表征和稳定性测试至关重要。